Dako Omnis Autostainer for Screening Tumor Tissues with Immunohistochemistry
Dako Omnis Autostainer 用于通过免疫组织化学筛查肿瘤组织
基本信息
- 批准号:8825649
- 负责人:
- 金额:$ 17.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2016-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesAutomationBasic ScienceBiological MarkersCancer Center Support GrantCell physiologyDetectionEnsureEquipmentFundingHistologyHousingHumidityImmunohistochemistryIn Situ HybridizationLongevityMalignant NeoplasmsMediatingMissionNeoplasm MetastasisPathologyPrincipal InvestigatorProcessReagentRecording of previous eventsResearchResearch PersonnelResource SharingResourcesRoswell Park Cancer InstituteRunningSlideStagingStaining methodStainsStandardizationSystemTemperatureTestingTherapeutic InterventionTimeTranslational ResearchTumor Tissueangiogenesisbasecancer diagnosiscostcost effectiveexperiencehuman tissueinstrumentmeetingsoutcome forecastpreventprotein expressionscreeningtumor growth
项目摘要
DESCRIPTION (provided by applicant): Roswell Park Cancer Institute (RPCI) seeks funds for the purchase of a Dako Omnis autostainer for immunohistochemistry (IHC). The instrument will be housed in the Pathology Resource Network facility (PRN) and overseen by Dr. Angela Omilian. The PRN is supported by a Cancer Center Support Grant and has been serving researchers as a formal shared resource core at RPCI for 7 years. The histology expertise associated with the PRN facility dates to even earlier; this facility has assisted investigators wih automated IHC since 2001. Thus, PRN staff is experienced and well-suited to operate and maintain the requested equipment. In a typical year, the PRN processes at least 7500 research IHC slides and uses two autostainers on a daily basis to meet this demand. Recently, one machine has been failing and is at the end of its useful lifespan. This is the impetus for our application. IHC is a straightforward, well-established, and cost-effective platform for the detection of protein expression in human tissue. In a research setting, IHC is often used to screen tumor tissues for biomarkers that can be used for cancer diagnosis, prognosis, staging, and/or as markers of therapeutic intervention. Automated IHC via the Dako Omnis permits an unprecedented level of standardization from run to run, quality, and also allows the PRN facility to process up to 120 research slides each workday, easily serving the needs of several investigators at RPCI at once. This application includes 16 principal investigators spanning a diverse range of basic and translational research, yet all sharing the common mission of RPCI: "To Understand, Prevent, and Cure Cancer." All users included in this application have a demonstrated history of using IHC to address translational research questions using biomarkers to signify the key cellular processes that are responsible for mediating tumor growth, angiogenesis, metastasis, and invasiveness. The requested Dako Omnis is superior to the current machinery used in the PRN for the following reasons: a) the Dako Omnis has temperature and humidity controls that permit an unprecedented level of standardization for antibody staining; b) the capability to run in situ hybridization simultaneously with IHC testing; ) an enhanced ability to run multiple slides for multiple investigators simultaneously and with ease; d) an increased slide capacity and shorter processing time allowing for greater throughput; e) uses less reagents permitting more slides per study for the same cost; f) a higher level of automation that reduces errors and ensures consistency. The Dako Omnis addresses all of the aforementioned factors in a way that is more controlled and comprehensive than any other staining system to date.
描述(由申请人提供):Roswell Park癌症研究所(RPCI)寻求资金购买免疫组织化学(IHC)用Dako Omnis自动染色仪。该仪器将存放在病理资源网络机构(PRN)中,并由Angela Omilian博士监督。PRN由癌症中心支持补助金支持,并已作为RPCI的正式共享资源核心为研究人员服务7年。与PRN机构相关的组织学专业知识可以追溯到更早的时候;该机构自2001年以来一直协助研究者进行自动化IHC。因此,PRN员工经验丰富,非常适合操作和维护所需设备。在典型的一年中,PRN处理至少7500个研究IHC载玻片,每天使用两台自动染色机来满足这一需求。最近,一台机器出现故障,其使用寿命即将结束。这是我们申请的动力。IHC是一种简单、成熟且具有成本效益的平台,用于检测人体组织中的蛋白质表达。在研究环境中,IHC通常用于筛选肿瘤组织中可用于癌症诊断、预后、分期和/或作为治疗干预标志物的生物标志物。通过Dako Omnis进行的自动化IHC实现了从运行到运行、质量的前所未有的标准化水平,还允许PRN机构每个工作日处理多达120个研究切片,轻松满足RPCI多名研究者的需求。该申请包括16名主要研究人员,他们跨越了基础和转化研究的不同领域,但都分享了RPCI的共同使命:“了解、预防和治愈癌症。“本申请中包含的所有用户都有使用IHC来解决转化研究问题的历史,这些问题使用生物标志物来表示负责介导肿瘤生长,血管生成,转移和侵袭性的关键细胞过程。申请的Dako Omnis上级PRN中使用的当前设备,原因如下:a)Dako Omnis具有温度和湿度控制,可实现前所未有的抗体染色标准化水平; B)能够同时进行原位杂交和IHC检测;)增强了为多名研究者同时轻松运行多个载玻片的能力; d)增加的载玻片容量和更短的处理时间,允许更大的通量; e)使用更少的试剂,允许在相同的成本下每次研究更多的载玻片; f)更高水平的自动化,减少错误并确保一致性。Dako Omnis以比迄今为止任何其他染色系统更可控和全面的方式解决了所有上述因素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Angela Omilian其他文献
Angela Omilian的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Angela Omilian', 18)}}的其他基金
Tumor and immune cell co-evolutionary dynamics as a source of racial disparities in breast cancer
肿瘤和免疫细胞共同进化动力学是乳腺癌种族差异的根源
- 批准号:
10673001 - 财政年份:2022
- 资助金额:
$ 17.5万 - 项目类别:
Tumor and immune cell co-evolutionary dynamics as a source of racial disparities in breast cancer
肿瘤和免疫细胞共同进化动力学是乳腺癌种族差异的根源
- 批准号:
10526731 - 财政年份:2022
- 资助金额:
$ 17.5万 - 项目类别:
The Role of Tumor-Infiltrating Immune Cells and Estrogen Receptor Expression in Racial Disparities in Breast Cancer Biology.
肿瘤浸润免疫细胞和雌激素受体表达在乳腺癌生物学种族差异中的作用。
- 批准号:
10058825 - 财政年份:2019
- 资助金额:
$ 17.5万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 17.5万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 17.5万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 17.5万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 17.5万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 17.5万 - 项目类别:














{{item.name}}会员




